1.
115例接受三线治疗的Ⅲb期/Ⅳ期肺癌患者的临床特征
The clinical characteristics of 115 stage Ⅲb/Ⅳ lung cancer patients receiving third-line therapy
| Variable | n (%) | EGFR-TKIs | Single-agent chemotherapy | Doublet chemotherapy | P |
| EGFR-TKIs: epidermal growth factor receptor-tyrosine kinase inhibitors | |||||
| Gender | 0.803 | ||||
| Male | 67 (58.3%) | 24 (54.5%) | 24 (61.5%) | 19 (59.4%) | |
| Female | 48 (41.7%) | 20 (45.5%) | 15 (38.5%) | 13 (40.6%) | |
| Performance status | 0.232 | ||||
| 0-1 | 78 (67.8%) | 34 (77.3%) | 24 (61.5%) | 20 (62.5%) | |
| ≥2 | 37 (32.2%) | 10 (22.7%) | 15 (38.5%) | 12 (37.5%) | |
| Median age at diagnosis | 0.402 | ||||
| ≥65 year | 29 (25.2%) | 14 (31.8%) | 9 (23.1%) | 6 (18.8%) | |
| < 65 year | 86 (74.8%) | 30 (68.2%) | 30 (76.9%) | 26 (81.3%) | |
| Smoking status | 0.045 | ||||
| No | 68 (59.1%) | 32 (72.7%) | 18 (46.2%) | 18 (56.3%) | |
| Yes | 47 (40.9%) | 12 (27.3%) | 21 (53.8%) | 14 (43.8%) | |
| Histology | 0.683 | ||||
| Adenocarcinoma | 92 (80.0%) | 37 (84.1%) | 30 (76.9%) | 25 (78.1%) | |
| Non-adenocarcinoma | 23 (20.0%) | 7 (15.9%) | 9 (23.1%) | 7 (21.9%) | |
| Staging | 0.401 | ||||
| Ⅳ | 83 (72.2%) | 30 (68.2%) | 27 (69.2%) | 26 (81.3%) | |
| Ⅲb | 32 (27.8%) | 14 (31.8%) | 12 (30.8%) | 6 (18.7%) | |
| Surgical history | 0.638 | ||||
| No | 96 (83.5%) | 35 (79.5%) | 34 (87.2%) | 27 (84.4%) | |
| Yes | 19 (16.5%) | 9 (20.5%) | 5 (12.8%) | 5 (15.6%) | |